|
|||||
|
|
Multiple potential targets of opioids in the treatment of acute respiratory distress syndrome from COVID-19 |
|
| Authors: | Cosmin Andrei Cismaru Gabriel Laurentiu Cismaru Seyed Fazel Nabavi Mostafa Ghanei Claudia Cristina Burz Seyed Mohammad Nabavi Ioana Berindan Neagoe |
| Institution: | 1. Research Center for Functional Genomics, Biomedicine and Translational Medicine, The “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania;2. Department of Internal Medicine, Cardiology-Rehabilitation, The “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania
Contribution: Conceptualization (equal), Writing - review & editing (equal);3. Applied Biotechnology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran Contribution: Conceptualization (equal), Writing - review & editing (equal);4. Chemical Injuries Research Center, Systems Biology and Poisoning Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran Contribution: Conceptualization (equal), Writing - review & editing (equal);5. Department of Functional Sciences, Immunology and Allergology, The “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania Contribution: Writing - review & editing (equal);6. Applied Biotechnology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran |
| Abstract: | COVID-19 can present with a variety of clinical features, ranging from asymptomatic or mild respiratory symptoms to fulminant acute respiratory distress syndrome (ARDS) depending on the host's immune responses and the extent of the associated pathologies. This implies that several measures need to be taken to limit severely impairing symptoms caused by viral-induced pathology in vital organs. Opioids are most exploited for their analgesic effects but their usage in the palliation of dyspnoea, immunomodulation and lysosomotropism may represent potential usages of opioids in COVID-19. Here, we describe the mechanisms involved in each of these potential usages, highlighting the benefits of using opioids in the treatment of ARDS from SARS-CoV-2 infection. |
| Keywords: | ARDS COVID-19 cytokine storm dyspnoea immunomodulation opioids |